hiv

Juan Berenguer REFERENCE: Abstract V-1385, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 JUAN BERENGUER, Hospital Gregorio Marañón, Madrid A ret

Moira McMahon REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 MOIRA MCMAHON, Johns Hopkins University, Baltimore The hepatitis B drug ente

Jeffrey Jacobson REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 JEFFREY JACOBSON, Drexel University College of Medicine, Philadelphia Cou

Jacob Lalezari REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007 JACOB LALEZARI, Quest Clinical Research, San Francisco Maraviroc could be a

Simon Lewin Adherence to TB Medication PLoS Med 4(7):e238. doi:10.1371/journal.pmed.0040238 SIMON LEWIN, London School of Hygiene and Tropical Medicine A new systematic review has shown that we don&#8

LISA McNALLY, Institute of Child Health, London, and University of KwaZulu-Natal, Durban REFERENCE: The Lancet 2007; 369:1440-1451 A new study suggests that current guidelines for the treatment of sev

ANTHONY FAUCI, National Institutes of Health, Bethesda REFERENCE: N Engl J Med 2007;356:2073-81 Is there any hope for an HIV vaccine? According to Anthony Fauci, of the National Institutes of Health i

DAVID MOORE, Imperial College, London and Lima REFERENCE: N Engl J Med 355: 1539-50 A new test for TB, trialled in Peru, has proved more powerful and yet faster and cheaper than alternatives, making i

HOOSEN COOVADIA, University of KwaZulu-Natal, Durban REFERENCE: Abstract 13, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February 25-28, 2007 In the developing world brea

HOWARD MAYER, Pfizer Global Research, New London CT MARK WAINBERG, McGill University, Montreal Abstract Number: 104aLB, 104bLB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angele

ROY STEIGBIGEL, State University of New York at Stony Brook JOHN W. MELLORS, University of Pittsburgh REFERENCE: Abstract 105aLB, 105bLB, 14th Conference on Retroviruses and Opportunistic Infections,

CHLOE THIO, Johns Hopkins University School of Medicine REFERENCE: Abstract: 136LB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February 25-28, 2007 Entecavir, used to tr

STEVEN GRINSPOON, Massachusetts General Hospital, Boston COMMENT: JUDITH CURRIER, University of California, Los Angeles REFERENCE: 14th Conference on Retroviruses and Opportunistic Infections, Los Ang

PHILIPPE MAYAUD, London School of Hygiene and Tropical Medicine REFERENCE: N Engl J Med 2007; 356: 790-9 In patients who are infected with both HIV and herpes simplex type 2 the activity of the AIDS v

RODGER MACARTHUR, Wayne State University, Detroit REFERENCE: Lancet 2006; 368: 2125-35 A three-class HIV antiretroviral therapy is not necessary, according to data published in the Lancet. The FIRST s

CHARLOTTE WATTS, London School of Hygiene and Tropical Medicine REFERENCE: Lancet 2006; 368: 1973-83 A large and groundbreaking study has shown that microfinance, combined with a gender and HIV traini

PAUL WEIDLE, Centers for Disease Control and Prevention, Atlanta REFERENCE: Lancet 2006; 368:1587-94 In rural sub-Saharan Africa there are many barriers to taking antiretroviral therapy successfully.

CHARLES HICKS, Associate Professor Medicine, Duke University, Durham REFERENCE: Lancet 2006; 368: 466-75 Results with a new antiretroviral agent, tipranavir, tested among patients who were resistant t

Roy Gulick, Weill Cornell Medical College, New York Although the logic in antiretroviral HIV therapy has, for some years, been that two drugs are better than one; and three are better than two, this h

Timothy Wilkin Timothy Wilkin, Weill Cornell Medical College, New York A protease inhibitor, currently known as TMC114 has been tested in the POWER II study among some 300 patients who had failed mult